BioRestorative Therapies Inc (OTCMKTS:BRTX) Major Shareholder Dale Broadrick Purchases 3,798,400 Shares

BioRestorative Therapies Inc (OTCMKTS:BRTX) major shareholder Dale Broadrick acquired 3,798,400 shares of the stock in a transaction dated Thursday, October 17th. The shares were acquired at an average cost of $0.13 per share, with a total value of $493,792.00. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Dale Broadrick also recently made the following trade(s):

  • On Thursday, August 22nd, Dale Broadrick acquired 175,017 shares of BioRestorative Therapies stock. The shares were acquired at an average cost of $0.28 per share, with a total value of $49,004.76.

OTCMKTS:BRTX opened at $0.15 on Wednesday. The stock has a 50-day simple moving average of $0.21 and a 200-day simple moving average of $0.37. BioRestorative Therapies Inc has a 1 year low of $0.08 and a 1 year high of $1.59.

BioRestorative Therapies (OTCMKTS:BRTX) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.24) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million during the quarter.

About BioRestorative Therapies

BioRestorative Therapies, Inc develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells for the treatment of disc/spine disease and metabolic disorders. The company's lead cell therapy candidate is the BRTX-100, which focuses on providing non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease.

Further Reading: Moving Average – How it Helps Investors in Stock Selection

Insider Buying and Selling by Quarter for BioRestorative Therapies (OTCMKTS:BRTX)

Receive News & Ratings for BioRestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit